Figure 1

- mAbs / fusion proteins
- G-CSF (including PEGylated G-CSF)
- Insulins (including analogues)
- Erythropoietins
- Somatropins
- Low-molecular weight heparins
- Others

2002 2003 2004 2005 2006 2007 2008 2009 2010 2011

MAA opinions by CHMP

Scientific Advice procedures

1st EMA Workshop on biosimilar mAbs

Regulatory commentary on biosimilar mAbs published

EMA/CHMP Concept paper on biosimilar mAbs

EMA/CHMP Draft Guideline on biosimilar mAbs

2nd EMA Workshop on biosimilar mAbs
Figure 2

(a) Overview of the biosimilar uptake in Denmark.

(b) Distribution of questions and major objections.

(c) Biosimilar uptake in Denmark:

<table>
<thead>
<tr>
<th>Year</th>
<th>Erythropoetin</th>
<th>Filgrastim</th>
<th>Somatropin</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2009</td>
<td>0</td>
<td>8.6</td>
<td>4.9</td>
</tr>
<tr>
<td>2010</td>
<td>6.4</td>
<td>4.9</td>
<td>0.1</td>
</tr>
<tr>
<td>2011</td>
<td>0.1</td>
<td>2</td>
<td>17.4</td>
</tr>
</tbody>
</table>